MedTrace Logo

A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN)

NCT00156078 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2021-01-25

No results posted yet for this study

Summary

A study of pregabalin efficacy and safety in a racially and culturally diverse group of subjects with painful diabetic peripheral neuropathy (DPN).

Conditions

  • Diabetic Neuropathy, Painful

Interventions

DRUG

pregabalin

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Completion
2007-05-31

Countries

  • Argentina
  • Brazil
  • Chile
  • Colombia
  • Ecuador
  • Indonesia
  • Jordan
  • Lebanon
  • Malaysia
  • Mexico
  • Philippines
  • Saudi Arabia
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • United Arab Emirates
  • Venezuela

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00156078 on ClinicalTrials.gov